← All trials
NCT05086939
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2021
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Oct 21, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL)Lead sponsor
- University of BarcelonaCollaborator
- Institut d'Investigacions Biomèdiques August Pi i SunyerCollaborator
- University of SalamancaCollaborator
- Spanish Clinical Research NetworkCollaborator
- University of SalamancaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.